Drug firm Lupin today said its Goa plant has completed inspection by the US drug regulator without any observations.
The company's Goa manufacturing facility has successfully completed prior approval inspection by the United States Food and Drug Administration (USFDA) without any observations, Lupin said in a statement.
The inspection which started on July 17 concluded today afternoon, it added.
Shares of Lupin Ltd today closed 1.99 per cent lower at Rs 1,142.85 per scrip on BSE.
Disclaimer: No Business Standard Journalist was involved in creation of this content
